| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/31/2023 | -19.92% | Piper Sandler | $19 → $21 | Maintains | Neutral |
| 06/30/2023 | -19.92% | Citigroup | $22 → $21 | Downgrades | Neutral → Sell |
| 05/01/2023 | -27.55% | Piper Sandler | $18 → $19 | Maintains | Neutral |
| 04/28/2023 | -4.67% | Stifel | $24 → $25 | Maintains | Hold |
| 04/18/2023 | -18.02% | B of A Securities | → $21.5 | Downgrades | Neutral → Underperform |
| 02/07/2023 | -0.86% | Citigroup | $21 → $26 | Maintains | Neutral |
| 01/09/2023 | — | B of A Securities | Upgrades | Underperform → Neutral | |
| 10/07/2022 | — | Citigroup | Upgrades | Sell → Neutral | |
| 09/26/2022 | -23.74% | Morgan Stanley | → $20 | Downgrades | Equal-Weight → Underweight |
| 08/01/2022 | -23.74% | Morgan Stanley | $22 → $20 | Maintains | Equal-Weight |
| 07/13/2022 | -16.11% | Morgan Stanley | $32 → $22 | Maintains | Equal-Weight |
| 05/02/2022 | 22.02% | Morgan Stanley | $35 → $32 | Maintains | Equal-Weight |
| 04/18/2022 | -18.78% | Piper Sandler | $19.5 → $21.3 | Downgrades | Neutral → Underweight |
| 04/11/2022 | 33.46% | Morgan Stanley | $30 → $35 | Maintains | Equal-Weight |
| 01/18/2022 | 14.39% | Morgan Stanley | $32 → $30 | Maintains | Equal-Weight |
| 12/07/2021 | 22.02% | Morgan Stanley | $34 → $32 | Maintains | Equal-Weight |
| 10/18/2021 | 22.02% | B of A Securities | $36 → $32 | Downgrades | Neutral → Underperform |
| 10/11/2021 | 29.65% | Morgan Stanley | $37 → $34 | Maintains | Equal-Weight |
| 08/03/2021 | 41.09% | Morgan Stanley | $40 → $37 | Maintains | Equal-Weight |
| 07/09/2021 | 52.53% | Morgan Stanley | → $40 | Downgrades | Overweight → Equal-Weight |
| 06/14/2021 | 37.27% | Citigroup | $30 → $36 | Downgrades | Neutral → Sell |
| 03/25/2021 | 44.9% | Morgan Stanley | $33 → $38 | Maintains | Overweight |
| 12/18/2020 | -31.36% | JP Morgan | → $18 | Downgrades | Neutral → Underweight |
| 11/10/2020 | — | Morgan Stanley | Upgrades | Equal-Weight → Overweight | |
| 10/26/2020 | -4.67% | Morgan Stanley | $24 → $25 | Maintains | Equal-Weight |
| 09/29/2020 | — | ABN Amro | Upgrades | Sell → Hold | |
| 07/27/2020 | -38.99% | Piper Sandler | $15 → $16 | Maintains | Neutral |
| 07/24/2020 | -16.11% | Stifel | $15 → $22 | Maintains | Hold |
| 07/16/2020 | -27.55% | Scotiabank | → $19 | Downgrades | Sector Outperform → Sector Perform |
| 07/08/2020 | -8.48% | Morgan Stanley | $18 → $24 | Maintains | Equal-Weight |
| 05/19/2020 | -31.36% | Morgan Stanley | $12 → $18 | Maintains | Equal-Weight |
| 04/24/2020 | -42.8% | Stifel | $14 → $15 | Maintains | Hold |
| 04/13/2020 | -50.43% | Scotiabank | $40 → $13 | Upgrades | Sector Perform → Sector Outperform |
| 04/07/2020 | -71.4% | Piper Sandler | $16.5 → $7.5 | Maintains | Neutral |
| 03/18/2020 | -46.62% | Stifel | $17 → $14 | Maintains | Hold |
| 03/17/2020 | -38.99% | JP Morgan | $39 → $16 | Maintains | Neutral |
| 03/16/2020 | -54.24% | Morgan Stanley | $45 → $12 | Maintains | Equal-Weight |
| 03/13/2020 | -58.06% | Citigroup | $40 → $11 | Maintains | Neutral |
| 03/10/2020 | -35.18% | Stifel | $40 → $17 | Maintains | Hold |
| 03/09/2020 | — | B of A Securities | Downgrades | Buy → Underperform | |
| 01/30/2020 | — | Johnson Rice | Reinstates | → Buy | |
| 01/14/2020 | 47.95% | Bernstein | → $38.8 | Initiates Coverage On | → Market Perform |
| 01/02/2020 | 52.53% | Stifel | $50 → $40 | Downgrades | Buy → Hold |
| 12/31/2019 | 48.71% | Cowen & Co. | $42 → $39 | Maintains | Market Perform |
| 12/10/2019 | 75.41% | Citigroup | $44 → $46 | Maintains | Neutral |
| 10/18/2019 | 67.78% | Citigroup | $51 → $44 | Maintains | Neutral |
| 10/07/2019 | 109.72% | Morgan Stanley | $65 → $55 | Maintains | Equal-Weight |
| 09/11/2019 | 94.47% | Citigroup | $54 → $51 | Maintains | Neutral |
| 07/12/2019 | 166.92% | Morgan Stanley | $75 → $70 | Maintains | Equal-Weight |
| 07/10/2019 | 140.23% | B of A Securities | → $63 | Upgrades | Neutral → Buy |
| 01/04/2019 | 151.67% | Citigroup | $76 → $66 | Maintains | Neutral |
| 12/19/2018 | 185.99% | Credit Suisse | $105 → $75 | Downgrades | Outperform → Neutral |
| 12/12/2018 | 201.24% | JP Morgan | $111 → $79 | Maintains | Neutral |
| 12/11/2018 | 201.24% | JP Morgan | $111 → $79 | Downgrades | Overweight → Neutral |
| 11/16/2018 | — | Guggenheim | Upgrades | Neutral → Buy | |
| 11/01/2018 | — | ABN Amro | Upgrades | Sell → Buy | |
| 10/29/2018 | 300.38% | Morgan Stanley | $115 → $105 | Maintains | Equal-Weight |
| 10/29/2018 | 319.45% | Stifel | $117 → $110 | Upgrades | Hold → Buy |
| 10/26/2018 | 300.38% | Credit Suisse | $122 → $105 | Maintains | Outperform |
| 10/11/2018 | 338.51% | Morgan Stanley | $125 → $115 | Maintains | Equal-Weight |
| 09/19/2018 | 376.64% | Morgan Stanley | → $125 | Initiates Coverage On | → Equal-Weight |
| 09/17/2018 | 361.39% | JP Morgan | $118 → $121 | Maintains | Overweight |
| 09/14/2018 | 342.33% | Citigroup | $117 → $116 | Maintains | Neutral |
| 09/11/2018 | 346.14% | Stifel | → $117 | Initiates Coverage On | → Hold |
| 09/04/2018 | — | Edward Jones | Initiates Coverage On | → Buy | |
| 08/14/2018 | — | Citigroup | Upgrades | Sell → Neutral |
What is the target price for Core Laboratories (CLB)?
The latest price target for Core Laboratories (NYSE: CLB) was reported by Piper Sandler on July 31, 2023. The analyst firm set a price target for $21.00 expecting CLB to fall to within 12 months (a possible -19.92% downside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Core Laboratories (CLB)?
The latest analyst rating for Core Laboratories (NYSE: CLB) was provided by Piper Sandler, and Core Laboratories maintained their neutral rating.
When is the next analyst rating going to be posted or updated for Core Laboratories (CLB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Core Laboratories, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Core Laboratories was filed on July 31, 2023 so you should expect the next rating to be made available sometime around July 31, 2024.
Is the Analyst Rating Core Laboratories (CLB) correct?
While ratings are subjective and will change, the latest Core Laboratories (CLB) rating was a maintained with a price target of $19.00 to $21.00. The current price Core Laboratories (CLB) is trading at is $26.23, which is out of the analyst's predicted range.